Cytospire Therapeutics announces oversubscribed £61 million Series A financing

Cytospire Therapeutics, a UK based biotech startup developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s own immune system, announces the closing of an oversubscribed £61 million ($83 million) Series A financing supported by ...